Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-proportionality of Vortioxetine ODT in Healthy Adults
NCT05416762Phase 1Completed
- Sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vortioxetine in major depressive disorder (MDD) (3 arms), sponsored by Seasons Biotechnology (Taizhou) Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 240 hours and Area Under the Curve from time zero to infinity at 240 hours. Started Sep 2022; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05416762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416762.